Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering Gains British Biotech's Marimastat, Drops U.S. Fareston Marketing

Executive Summary

Schering-Plough will assume all European and U.S. regulatory filings for British Biotech's cancer therapy marimastat under a collaboration announced September 7 to develop and market British Biotech's matrix metalloproteinase inhibitors.

You may also be interested in...



Aeterna Neovastat Will Be 12th Antiangiogenesis Drug To Reach Phase III

Aeterna Labs' Neovastat will begin patient enrollment for a Phase III clinical trial in non-small cell lung cancer in March, CEO Eric Dupont reported Feb. 16 at the Biotechnology Industry Organization CEO and Investor Conference in New York City.

Aeterna Neovastat Will Be 12th Antiangiogenesis Drug To Reach Phase III

Aeterna Labs' Neovastat will begin patient enrollment for a Phase III clinical trial in non-small cell lung cancer in March, CEO Eric Dupont reported Feb. 16 at the Biotechnology Industry Organization CEO and Investor Conference in New York City.

British Bio Seeking Partners For Three Projects After Zacutex Termination

British Biotech will focus its discovery research on metallo-enzyme inhibition programs and seek partnerships for several compounds following the discontinuation of the pancreatitis therapy Zacutex (lexipafant), the firm announced March 25.

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel